A Study of HS-20089 in Patients With Advanced Solid Tumors

NCT05263479 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: HS-20089 (Phase Ia：Dose escalation )
DRUG: HS-20089 (Phase Ib: Dose expansion)

Sponsor

Shanghai Hansoh Biomedical Co., Ltd